• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nature Viral and Host Factors Related to the Clinical Outcome of COVID-19

tetano

Editor, Senior Moderator
Nature


. 2020 May 20.
doi: 10.1038/s41586-020-2355-0. Online ahead of print.
Viral and Host Factors Related to the Clinical Outcome of COVID-19


Xiaonan Zhang[SUP] 1 [/SUP], Yun Tan[SUP] 2 [/SUP], Yun Ling[SUP] 1 [/SUP], Gang Lu[SUP] 2 [/SUP], Feng Liu[SUP] 2 [/SUP], Zhigang Yi[SUP] 1 3 [/SUP], Xiaofang Jia[SUP] 1 [/SUP], Min Wu[SUP] 1 [/SUP], Bisheng Shi[SUP] 1 [/SUP], Shuibao Xu[SUP] 1 [/SUP], Jun Chen[SUP] 1 [/SUP], Wei Wang[SUP] 1 [/SUP], Bing Chen[SUP] 2 [/SUP], Lu Jiang[SUP] 2 [/SUP], Shuting Yu[SUP] 2 [/SUP], Jing Lu[SUP] 2 [/SUP], Jinzeng Wang[SUP] 2 [/SUP], Mingzhu Xu[SUP] 1 [/SUP], Zhenghong Yuan[SUP] 3 [/SUP], Qin Zhang[SUP] 4 [/SUP], Xinxin Zhang[SUP] 5 [/SUP], Guoping Zhao[SUP] 6 [/SUP], Shengyue Wang[SUP] 7 [/SUP], Saijuan Chen[SUP] 8 [/SUP], Hongzhou Lu[SUP] 9 [/SUP]



Affiliations

Abstract

In December 2019, the Coronavirus disease 2019 (COVID-19), caused by a novel coronavirus SARS-CoV-2, emerged in Wuhan, Hubei province, China[SUP]1[/SUP] and soon spread across the world. In this ongoing pandemic, public health concerns and the urgent need for effective therapeutic measures require a deep understanding of its epidemiology, transmissibility and pathogenesis. Here we analyzed the clinical, molecular and immunological data from 326 confirmed cases of COVID-19 in Shanghai. Genomic sequences of SARS-CoV-2 assembled from 112 quality samples together with sequences in the Global Initiative on Sharing All Influenza Data (GISAID) showed a stable evolution and suggested two major lineages with differential exposure history during the early phase of the outbreak in Wuhan. Nevertheless, they exhibited similar virulence and clinical outcomes. Lymphocytopenia, especially the reduced CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T cell counts upon admission, was predictive of disease progression. High levels of IL-6 and IL-8 during treatment were observed in patients with severe or critical disease and correlated with decreased lymphocyte count. The determinants of disease severity seemed to stem mostly from host factors such as age, lymphocytopenia, and its associated cytokine storm, whereas viral genetic variation did not significantly affect the outcomes.
 
Back
Top Bottom